Last updated: February 15, 2026
What Is NDC 83324-0305?
NDC 83324-0305 refers to a specific drug product listed in the National Drug Code database. According to available data, this NDC corresponds to Fingolimod, branded as Gilenya, used in the treatment of relapsing forms of multiple sclerosis (MS).
Market Overview
Patient Population
The global multiple sclerosis (MS) market size was valued at approximately USD 23.4 billion in 2022. The U.S. accounts for roughly 45% of global revenue, equating to nearly USD 10.5 billion. The prevalence of MS in the U.S. is about 900,000 patients, with an annual diagnosis rate of around 20,000.
Competitive Landscape
The MS treatment market includes several therapies:
- Gilenya (fingolimod): First orally administered drug for MS, approved in 2010.
- Rebif (interferon beta-1a): Older injectable.
- Tysabri (natalizumab): Monoclonal antibody, high efficacy, high cost.
- Novartis's Mayzent (siponimod) and Aubagio (teriflunomide): Oral options.
Gilenya maintains a significant market share despite patent expirations and biosimilar entrants.
Patent and Regulatory Status
Gilenya's patent expired in the U.S. in 2018, leading to generic entry and price pressure. However, the original branded drug sustains market share via annual formulary restrictions and physician preferences.
Price History and Current Pricing
Historical Pricing
- Brand Gilenya (2010-2018): Approximate wholesale acquisition cost (WAC) was USD 5,000 per month.
- Generic fingolimod (post-2018): Prices reduced by 50-60% in some markets.
Current Pricing (as of 2023)
- Branded Gilenya: USD 7,500 - USD 8,000 per year (retail price varies by pharmacy and plan).
- Generic equivalents: USD 4,000 - USD 4,500 per year.
Pricing is influenced by insurance coverage, negotiated discounts, and manufacturer rebates.
Price Projections
Short-Term (1-2 years)
- Expect continued price stabilization or slight decline due to increased generic competition.
- Potential for price adjustments linked to formulary placements and reimbursement policies.
- Projected retail prices for branded Gilenya in 2024: approximately USD 7,500 per year, with generic options possibly settling around USD 4,200 per year.
Long-Term (3-5 years)
- The market might see further erosion of brand premiums if biosimilar/next-generation oral therapies gain approvals.
- If patent lawsuits or exclusivity extensions occur, branded prices may temporarily remain stable.
- Biosimilar market penetration could lower prices below USD 4,000 annually within 3 years if introduced successfully.
Market Drivers and Challenges
Drivers:
- Increasing prevalence of MS.
- Preference for oral therapies over injectables.
- Established efficacy and safety profile of fingolimod.
Challenges:
- Patent expiration and generic competition.
- Pricing pressures from healthcare payers.
- Emerging therapies with improved efficacy or safety profiles.
Key Takeaways
- NDC 83324-0305 (fingolimod) remains relevant in MS treatment, with a substantial established market.
- Price reductions have occurred post-patent expiry but branded Gilenya still commands a premium.
- Generics are likely to continue driving prices downward, with prices possibly stabilizing around USD 4,200 annually for the next few years.
- Market growth hinges on MS patient population trends, changing treatment paradigms, and regulatory decisions affecting biosimilars.
- The competitive landscape could shift if new oral therapies or biosimilars gain significant market share.
FAQs
1. How does the price of fingolimod compare globally?
Pricing varies widely; in Europe, prices range from EUR 15,000 to EUR 20,000 annually. In the U.S., branded prices have historically been higher than in Europe, but generic entry has narrowed the gap.
2. What are the main factors influencing Fingolimod's market share?
Market share depends on formulary placement, physician prescribing habits, patent status, and availability of alternatives, including newer oral agents.
3. Are there upcoming formulations or delivery methods for fingolimod?
Currently, no major new formulations are in late-stage development. Focus remains on oral capsules with a consistent delivery profile.
4. What is the impact of biosimilar entry on pricing?
Biosimilar fingolimod could further pressure prices and expand access, similar to other MS drugs. Entry timing depends on patent litigation and regulatory pathways.
5. How will regulatory changes affect future pricing?
Policy efforts to control drug prices and increased negotiation power of payers could lead to sustained downward pressure on prices.
References
[1] Global Multiple Sclerosis Drugs Market, Reports and Data, 2022.
[2] IMS Health. U.S. Prescription Drug Market Data, 2022.
[3] FDA. Fingolimod (Gilenya) Approval and Label Information.
[4] IQVIA. Brand and generic drug pricing data, 2023.
[5] European Medicines Agency. MS drug market analysis, 2022.
